SHALBY LIMITED
•Passion••Compassion••Innovation•

Shalby/SE/2026-27/39 August 12, 2026

The Listing Department
National Stock Exchange of India Ltd
Mumbai 400 051.

Scrip Code : SHALBY
Through : https://neaps.nseindia.com/NEWLISTINGCORP/

Corporate Service Department
BSE Limited
Mumbai 400 001.

Scrip Code: 540797
Through : http://listing.bseindia.com

Sub: Investor Presentation for the quarter ended 30th June 2026

Dear Sir / Madam,

We are submitting herewith Investor Presentation on financial & operational performance of the Company for the Quarter ended June 30, 2026, which will be discussed at the Investor Conference call scheduled tomorrow i.e. on August 13, 2026 at 10:30 a.m IST.

The said Investor Presentation is being uploaded on website of our Company at https://www.shalby.org/investors/ → Investors Presentation.

You are requested to take the same on your record.

Thanking you,

Yours sincerely
For **Shalby Limited**
SHAH TUSHAR DINESHCHANDRA
Digitally signed by SHAH TUSHAR DINESHCHANDRA
Date: 2026.08.12 19:28:11 +05'30'
Tushar Shah
Vice President & Company Secretary
Mem. No: FCS-7216

Encl.: Investor Presentation

SHALBY LIMITED

•Passion••Compassion••Innovation•

Investor Presentation

Q1 FY2027

DISCLAIMER

This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful.

This presentation has been prepared by **Shalby Limited (the "Company")**. These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States.

The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction.

No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point.

This presentation contains certain "forward looking statements". Forward-looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward-looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose. No responsibility or liability whatsoever is undertaken for the contents hereof.

This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm.

AGENDA

Financials Snapshot Q1 FY27

SHALBY LIMITED
•Passion••Compassion••Innovation•

Consolidated Financial Highlights

- Consolidated Total Revenue at ₹ 3,386 mn in Q1 FY27 vs ₹ 3,034 mn in Q1 FY26
- Consolidated EBITDA at ₹ 490 mn in Q1 FY27 vs ₹ 485 mn in Q1 FY26
- Consolidated PBT at ₹ 197 mn in Q1 FY27 vs ₹ 227 mn in Q1 FY26
- Consolidated PAT at ₹ 105 mn in Q1 FY27 vs ₹ 77 mn in Q1 FY26
- Consolidated Annualized ROCE stood at 6.7%

Standalone Financial Highlights

- Standalone Total Revenue at ₹ 2,591 mn in Q1 FY27 vs ₹ 2,422 mn in Q1 FY26
- Standalone EBITDA at ₹ 478 mn in Q1 FY27 vs ₹ 524 mn in Q1 FY26
- Standalone PBT at ₹ 339 mn in Q1 FY27 vs ₹ 401 mn in Q1 FY26
- Standalone PAT at ₹ 251 mn in Q1 FY27 vs ₹ 257 mn in Q1 FY26
- Standalone Annualized ROCE stood at 9.4%

Consolidated Performance Highlights – Q1 FY27

SHALBY MULTI-SPECIALTY HOSPITALS

Financial Performance (in INR Mn)

Total Revenue



EBITDA[1] & Margin



PBT & Margin



PAT & Margin



1. EBITDA includes other income

Consolidated P/L & B/S – Q1 FY27

SHALBY LIMITED
•Passion••Compassion••Innovation•

Profit & Loss

Particulars (INR Mn)	Q1 FY27	Q4 FY26	Q1 FY26	Q-o-Q Growth	Y-o-Y Growth
Total Revenue	**3386**	**2955**	**3034**	**14.6%**	**11.6%**
EBITDA[2]	**490**	**374**	**485**	**30.9%**	**0.9%**
EBITDA Margin %	*14.5%*	*12.7%*	*16.0%*		
PBT	**197**	**96**	**227**	**105.0%**	**(13.1%)**
PBT Margin %	*5.8%*	*3.3%*	*7.5%*		
PAT	**105**	**185**	**77**	**(43.1%)**	**36.7%**
PAT Margins %	*3.1%*	*6.2%*	*2.5%*		

Balance Sheet (INR Mn)

Gross Borrowings	5509
Cash & Cash Equivalents	873
Net Cash/(Debt)	(4636)
Debt/Equity	0.46x
ROCE[1]	6.7%

Notes:
1. ROCE= Annualized EBIT/ Average (Equity +Debt- Cash & Cash Equivalent) 2. EBITDA includes other income.

Shalby Limited : Consolidated Revenue & EBITDA Breakup – Q1 FY27

SHALBY LIMITED
•Passion••Compassion••Innovation•

	Revenue (%)	Revenue (in INR Mn)	EBITDA (in INR Mn)
Shalby Hospitals, Pharma & Franchise[1]	78.32%	2652.2	450.5
Shalby International (PK Healthcare, Delhi-NCR)[2]	7.75%	262.3	39.2
Shalby MedTech (Implant Business)	13.92%	471.7	1.6
Others	0.01%	0.2	(1.3)
Shalby Limited (Consolidated)	100%	3386.4	490.0

Notes:
1. Includes Shalby Academy, Slaney and Griffin which is into pharmacy trading 2.Includes fellow subsidiaries in Delhi-NCR region.

Financial Trends – Shalby Limited (Consolidated)

SHALBY LIMITED
•Passion••Compassion••Innovation•

Total Revenue (In INR Crs)



EBITDA (In INR Crs) & Margin (%)



ROCE (%)



SHALBY LIMITED BUSINESS VERTICALS

SHALBY
MULTI-SPECIALTY
HOSPITALS

SHALBY
MedTech

A Legend and Visionary Doctorpreneur behind Shalby

Dr Vikram I Shah,
Founder & Chairman

Dr Vikram I. Shah, the Founder of Shalby Ltd, is a world-renowned Joint Replacement Surgeon who innovated the **"Zero Technique"** that revolutionized Joint Replacement Surgery.

A visionary entrepreneur, he transformed Shalby from a 6-bedded hospital in 1994 to an integrated healthcare group with 13 hospitals network and 2200+ beds across 10 cities in India, with an implant manufacturing facility in California, USA and a distribution facility in India and South-East Asian countries.

Shalby is today the Biggest Corporate Hospital Group in Western and Central India, focusing on all major disciplines in medicine, with credentials of being the Largest Joint Replacement Centre of the World, having done over 1,75,000+ successful joint replacement surgeries till date.

Shalby Limited is listed on both the premier stock exchanges in India and has the aspiration of growing multifold while preserving the core values of "Passion, Compassion and Innovation".

STANDALONE BUSINESS PERFORMANCE

Standalone Business Highlights – Q1 FY27

SHALBY MULTI-SPECIALTY HOSPITALS

Financial Performance (in INR Mn)

Total Revenue



EBITDA[1] & Margin



PBT & Margin



PAT & Margin



1. EBITDA includes other income

Standalone Business P&L and B/S – Q1 FY27

Profit & Loss

Particulars (INR Mn)	Q1 FY27	Q4 FY26	Q1 FY26	QoQ Growth	YoY Growth
Total Revenue	**2591**	**2304**	**2422**	**12.4%**	**7.0%**
EBITDA[2]	**478**	**371**	**524**	**28.9%**	**(8.8%)**
EBITDA Margin %	*18.4%*	*16.1%*	*21.6%*		
PBT	**339**	**235**	**401**	**44.4%**	**(15.5%)**
PBT Margin %	*13.1%*	*10.2%*	*16.6%*		
PAT	**251**	**537**	**257**	**(53.3%)**	**(2.4%)**
PAT Margin %	*9.7%*	*23.3%*	*10.6%*		

Total Revenue to EBITDA



Balance Sheet as of June '26 (INR Mn)

Gross Borrowings	**1215.69**
Cash & Cash Equivalents	**670.86**
Net Cash/(Debt)	**(544.83)**
ROCE[1] (annualized)	**9.4%**

Notes:

1. **ROCE= Annualized EBIT/ Average (Equity +Debt- Cash & Cash Equivalent) 2. EBITDA includes other income.**

Shalby International Q1’FY27 Highlights

Total Revenue of ₹262.3 Mn. in Q1’FY27 vs ₹232.5 Mn. in Q1’FY26

ARPOB ₹91,326

ALOS 3.80

Occupancy Rate 24%

IP Count 1200+

OP Count 4650+

Patients across 60+ countries

42% revenue generated from international patients

Total Bed Capacity 130

Expertise in Liver, Kidney, Blood & Bone Marrow Transplant

Total Employees 240+

Doctors & Consultant 45+

Nursing 75+

Support Staff 80+

Technician 40+

18900+ Patients Served in FY25-26

1700+ Total Surgeries in 15+ Specialties in FY25-26

Notes:
ALOS is calculated without daycare.

Shalby International Performance Highlights – Q1 FY27

Revenue (INR MN)



EBITDA (INR MN)



PBT (INR MN)



PAT (INR MN)



1. EBITDA includes other income

Hospital Business Highlights Q1 FY27

SHALBY MULTI-SPECIALTY HOSPITALS

Surgery Count and YoY Performance

Arthroplasty
3830+ ↓ 9.2%

Orthopaedic
1420+ ↑ 5.0%

Oncology
495+ ↔

General & Cosmetics
1010+ ↔

Nephro & Urology
1120+ ↑ 55.6%

Other Surgery
1,430+ ↑ 21.9%

Operational Performance[3]

Particulars	Q1 FY27	Q1 FY26	YoY Growth
In-Patient[1] (Nos.)	23,895	22,499	6.2%
Out Patient (Nos.)	1,28,139	1,34,122	(4.5%)
Surgeries Count	9,326	9,013	3.5%
ARPOB (In Rs.)	44,711	45,673	(2.1%)
Operational Beds[2] (Nos.)	1,365	1,415	(3.5%)
Occupied Beds	701	639	9.8%
Occupancy Rate[4]	51%	45%	624bps
ALOS (without Daycare)	3.69	3.53	4.5%

Notes:
1. In-Patient count Includes Day care count 2. Included operational beds in (FOSO) SOCE unit 3.Q1'FY27 & Q1'FY26 numbers include PK Healthcare performance. 4. Occupancy Rate excluding PK Healthcare is 54%.

Hospital Business Highlights

Speciality Revenue Mix

Q1 FY2026 [2]



Q1 FY2027 [2]



Notes:
1. Orthopaedic includes Spine. 2. .Q1'FY26 & Q1'FY27 numbers include PK Healthcare performance.

Hospital Business Highlights

Payor Mix

Q1 FY2026[1]



Q1 FY2027[1]



Notes:

1. **Q1'FY26 & Q1'FY27 numbers include PK Healthcare performance.**

Maturity Wise Hospital Performance – Q1 FY27[1]

SHALBY LIMITED
•Passion••Compassion••Innovation•

Maturity	No. of Hospitals	Total Revenue (in INR Mn)	Operational Beds	ARPOB	EBITDA (in INR Mn)	EBITDA Margin (in%)
10+ Years	7	1612.2	808	48,880	371.0	23.0%
5-10 Years	3	927.9	427	33,197	161.3	17.4%
0-5 Years	1	262.3	130	91,326	18.2	6.9%
Corporate[2,3]	-	50.5	-	-	(54.7)	(108.3%)
Total	11	2852.9	1365	44,711	495.8	17.4%

Notes:
1. Q1'FY27 numbers include PK Healthcare performance 2. Corporate revenue includes MF gains & FD interest, FOSM revenue sharing (Franchise Network- Zynova and Gwalior), interest and corporate guarantee commission income from inter-company loans. 3. EBITDA loss includes Corporate employees' expense and other common administrative expenses.

Financial Trends – Standalone Business [1]

SHALBY LIMITED
•Passion••Compassion••Innovation•

Total Revenue (In INR Cr)



EBITDA (In INR Cr) & Margin (%)



PAT (In INR Cr) & Margin (%)



ROCE (%)



Notes:
1. Above metrics are excluding of PK Healthcare & FOSM.

Operational Trends – Hospital Business [1,2]

SHALBY LIMITED
•Passion••Compassion••Innovation•

Bed Capacity



Operational Beds



Occupied Beds



Total Surgeries Count



ARPOB (in INR)



ALOS



Notes:
1. Above metrics are inclusive of PK Healthcare & FOSO. 2.Bed Capacity includes PK Healthcare, FOSO & Shalby Zynova.

Key Focus Areas For Future In Hospital business

Global Leader in Joint Replacement with diversification in other specialties
- Continue to maintain global leadership in joint replacements
- Ongoing diversification with Cardiac Science, Oncology, Neuro-science, Critical Care, General Medicine and Transplants

Prudent Capital Allocation
- Sustainable Capex business model whereby becoming a preferred O&M partner on revenue sharing mode
- Focus to doubling ROCE in coming year due to operational leverage

Growth in Occupancy Rate
- Additional 40% of the total bed capacity is available to support organic growth trajectory with limited capex

Training and Development
- Investment in high impact training programs will establish a dedicated professional medical base

24x7 Homecare Services
- Provide Quality Services Through High-end digital systems
- Growing no of services and markets outside home locations

Leveraging Technology
- Adoption and leveraging technology to provide better medical outcomes, patient reach and satisfaction

Expansion Plan
- Mumbai hospitals within development budget and provide access to important local markets

SHALBY MedTech

SAT Inc.
RESTORING MOBILITY, IMPROVING LIVES.

SHALBY Global Technologies Pte. Ltd.

SAT India Pvt. Ltd.
RESTORING MOBILITY, IMPROVING LIVES.

IMPLANT BUSINESS



Shalby's Company Structure of Implant Business



*** Shalby MedTech Limited (SMTL) formerly known as Mars Medical Devices Limited. (MMDL)**

Shalby MedTech Performance Highlights: Q1 FY27

SHALBY MedTech

Financial Performance (in INR Mn)

Total Revenue



	SMTL	SAT, Inc.	SGTPL	SMTL Consol.
Q1 FY26	182.44	302.06	3.64	308.25
Q4 FY26	280.89	326.03	12.88	402.68
Q1 FY27	360.96	328.10	9.87	471.67
QoQ Growth %	29%	1%	-23%	17%
YoY Growth %	98%	9%	171%	53%

Total EBITDA



	SMTL	SAT, Inc.	SGTPL	SMTL Consol.
Q1 FY26	12.79	(18.12)	(2.27)	(7.48)
Q4 FY26	10.12	146.00	(5.94)	37.16
Q1 FY27	29.41	(6.02)	5.79	1.65
QoQ Growth %	191%	-104%	197%	-96%
YoY Growth %	130%	67%	355%	122%

Shalby MedTech Financial Historical Trend

Financial Performance (in INR Mn)

Total Revenue



	SMTL	SAT, Inc.	SGTPL	SMTL Consol.
FY 24	156.74	786.02	14.49	584.41
FY 25	352.04	1,081.82	63.72	922.86
FY 26	813.11	1,168.23	63.05	1,349.72
YoY Growth %	131%	8%	-1%	46%

Total EBITDA



	SMTL	SAT, Inc.	SGTPL	SMTL Consol.
FY 24	(17.25)	1.18	(8.00)	(48.52)
FY 25	(116.76)	(77.92)	9.91	(191.65)
FY 26	(7.10)	210.15	(0.99)	67.04
YoY Growth %	94%	370%	-110%	135%

Shalby MedTech Consolidated Inventory



	Days of Inventory to Sales (in Days)	Consol. Total Revenue	Consol. Total Inventory	FG	RM+WIP
Q1 FY27	651	472	3,374	2,452	922
FY26	934	1,350	3,454	2,534	920
FY25	1,153	923	2,914	2,028	886
FY24	1,315	584	2,106	1,562	544

Q1 FY27 FY26 FY25 FY24

CORE STRATEGIC PILLARS

SHALBY MedTech

- Recruitment, retention & training of sales and corporate teams.
- Strong employee engagement, involvement and regular communication.
- Clear career development pathway.
- Rewards and recognition.
- Annual goals and performance planning.



- Continual training of employees, HCPs and Channel Partners.
- Solid Partner Relationship.
- Achieve industry-best talent.
- Implement robust succession planning process.
- Scale leadership development programs.

Implant Business Footprint Global

SHALBY MedTech

Existing Markets

- North America
- Japan
- India
- Indonesia

Approval Received

- Malaysia (Knee)
- Vietnam (Hip)
- Nepal
- Burma
- Brunei

Upcoming Markets

- Argentina
- Peru
- Colombia
- Iran
- Iraq
- Paraguay

Implant Business Footprint Across India

Existing Markets

- Andhra Pradesh
- Chhattisgarh
- Gujarat
- Haryana
- Karnataka
- Madhya Pradesh
- Maharashtra
- Punjab
- Rajasthan
- Tamil Nadu
- Telangana
- West Bengal

Upcoming Markets

- Assam
- Odisha
- Uttar Pradesh
- Uttarakhand

Marketing Engagements

EVENT HIGHLIGHTS · APRIL – MAY 2026

Building Momentum Early in the Quarter



5–6 APR 2026

National Sales Kick-Off · Jaipur

Brought together sales and leadership teams from across the country to align on business strategy, product updates and sales planning for the year ahead. Outstanding performers were recognized, strengthening collaboration to drive growth and customer excellence.

5 APR 2026

BOSCON 2026

Connected with leading orthopedic surgeons and industry professionals. The conference provided a platform to showcase our orthopedic solutions, exchange clinical insights, and strengthen collaborations within the orthopedic community.

23–24 MAY 2026

DAA Workshop · Bengaluru

At M S Ramaiah Institute, orthopaedic surgeons came together for an immersive two-day Direct Anterior Approach (DAA) Hip Arthroplasty learning experience — combining structured cadaveric education with live surgical observation.

Marketing Engagements

EVENT HIGHLIGHTS · JUNE – AUGUST 2026

Deepening Surgeon Engagement

14–15 JUN 2026

Guwahati Knee Course

A 2-day program bringing together leading orthopedic surgeons for scientific discussions, expert-led sessions, and the exchange of the latest advancements in knee arthroplasty — reinforcing our commitment to orthopedic education.

28 JUN 2026

Ahmedabad Orthopaedic Society Conference

Participated in “Fracta Vincimus,” featuring insightful sessions on fracture management, Hip Arthroplasty and Revision Hip Arthroplasty — an excellent platform for learning and collaboration with leading orthopedic surgeons.

31 JUL – 2 AUG 2026

Delhi Conference

Focused on brand building, surgeon interactions, and creating awareness about our products among the orthopedic community in Delhi.

ABOUT SHALBY LIMITED

Shalby At A Glance

SHALBY LIMITED
•Passion••Compassion••Innovation•

Presence

13
Hospitals[1]

OPD clinics

60
Domestic

23
International[2]

Orthopedic Implant Manufacturing in USA

Strength

2,200+
Bed Capacity

4,500+
Total Employees[3]

1,150+
Doctors[4] Team

32
Years of Legacy

Clinical Excellence

30+
Specialties

~3.5 million+
Patients Served[5]

175,000+
Joint Replacements

#1
Global Ranking in Arthroplasty

1. 11 Multispecialty and 2 Single Speciality, 2. East African Countries, Iraq, CIS, Dubai, Oman, Bangladesh and Nepal. 3. Including Doctors, 4. Including visiting consultants, 5. Since Inception

32 Years of ELITE Legacy

SHALBY LIMITED
•Passion••Compassion••Innovation•

Integrity

Highest standards of transparency accountability, and corporate governance

Learning

Laser sharp focus on upgrading the skills of our team and building people capability ensuring high levels of patient care

Team-Work

A patient-centric focused team with a great blend of experience, diversity, fresh thinking, with proven excellence in service

Excellence

Proven leadership in healthcare, setting up Centre of Excellence to capture massive opportunities

Empathy

Creating an equitable healthcare system keeping interests of patients and families at the focus

Our Journey & Expansion Plan

1994

Vijay Shalby, Ahmedabad

27 beds

2007

SG Shalby, Ahmedabad

201 beds

2012

- Vapi Shalby, Vapi (**146 beds**)
- Krishna Shalby, Ahmedabad (**220 beds**)

2015

- Jabalpur Shalby, Jabalpur (**233 beds**)
- Indore Shalby, Indore (**243 beds**)
- Mohali Shalby, Mohali (**145 beds**)

2017

- Jaipur Shalby, Jaipur (**237 beds**)
- Naroda Shalby, Ahmedabad (**267 beds**)
- Surat Shalby, Surat (**243 beds**)
- Zynova[1] Shalby, Mumbai (**100 beds**)

2021

- Acquired Implant Manufacturing Unit at California, **USA**

2022

- Gwalior[1] SOCE, **50 beds**

2024

- Shalby International, Gurugram, **130 beds**
- Acquired 100% stake in **Healers Hospital Pvt Ltd.**

2030-31

- Asha Parekh Hospital, Mumbai **(200 beds)**

Note:
1. Zynova & Gwalior is operating on Revenue sharing business model

SHALBY MULTI-SPECIALTY HOSPITALS

Hospitals Portfolio

SHALBY MULTI-SPECIALTY HOSPITALS

Multispecialty Hospital Units

SG Shalby



Vapi Shalby



Indore Shalby



Jaipur Shalby



Krishna Shalby



Mohali Shalby

Naroda Shalby



Jabalpur Shalby

Surat Shalby



Shalby International

BIGGEST HEALTHCARE CORPORATE GROUP IN WESTERN AND CENTRAL INDIA

Domestic Presence



PUNJAB
- Mohali – 145 beds

DELHI
- Gurugram – 130 beds

RAJASTHAN
- Jaipur – 237 beds

GUJARAT
- Ahmedabad
  - SG – 201 beds
  - Krishna – 220 beds
  - Naroda – 267 beds
  - Vijay – 27 beds
- Vapi – 146 beds
- Surat – 243 beds

MADHYA PRADESH
- Indore – 243 beds
- Jabalpur – 233 beds

MAHARASHTRA
- Ghatkopar (Zynova) – 100 beds

Madhya Pradesh
Gwalior – 50 beds

OPDs Owned Franchise

International OPDs



SHALBY MULTI-SPECIALTY HOSPITALS

Note:
- Franchise Network- Zynova and Gwalior are under FOSM operating model.

www.shalby.org

Shalby Limited Shareholding Pattern (as on 30th June'26)



Experienced Board Of Directors

SHALBY LIMITED
•Passion••Compassion••Innovation•

Dr. Vikram Shah
Chairman and Managing Director

Dr. Vikram Shah, serving as Director of the Department of Knee Replacement at Shalby Hospitals since 1993 has nearly three decades of vast professional healthcare experience across the UK, USA and India. In recognition of his outstanding contribution in the field of orthopedics for completion of 1,75,000 joint replacement surgeries, he was conferred with the 'Times Man of the Year' Award by Times of India Group in 2018.

Dr. Ashok Bhatia
Independent Director

Mr. Ashok Bhatia is an experienced Pharmaceutical executive with over 48 years of leadership spanning sales, marketing, business development, M&A, and talent management. He dedicated 37 years to Zydus Lifesciences, where he rose to the position of President – Emerging Markets, overseeing operations across 12 markets and managing a team of over 800 professionals. He holds a Doctorate in Business Administration (DBA), an MBA, and a B.Sc., and is a guest faculty at IIM Ahmedabad and IIM Rohtak, specialising in International Marketing and Talent Management. His article 'Gender and Workplace' has been published in VIKALPA, the journal of IIM Ahmedabad.

Mr. Shyamal Joshi
Independent Director

Associated with Shalby Hospitals since 2010, Mr. Joshi holds a bachelor's degree in commerce from Gujarat University and is a member of the ICAI. He has huge working experience that spans corporate strategy, fund raising, acquisition, merger, taxation and accounting among others. Currently, he holds directorship of various other Companies.

Mr. Tej Malhotra
Independent Director

Mr. Malhotra comes with over four decades of experience across various industries in India and internationally. Earlier, he was associated with GHCL as Senior Executive Director, Idea Soda Ash and Calcium Chloride Company of Saudi Arabia as Technical Director and as Executive Engineer (Mechanical) at Hindustan Copper. He has been awarded the 'Bhartiya Udyog Ratan' award by the Indian Economic Development and Research Association, the 'Bhartiya Gaurav' award by the World Economic Progress Society and 'Darbari Seth Award 2009' by the Alkali Manufacturers of India for best managed soda-ash plant.

Dr. Umesh Menon
Independent Director

Dr. Menon has deep expertise in finance and cost accounting. He also holds MBA with specialization in Finance, and a fellow member of Institute of Cost Accountants of India. He has been conferred with the Doctorate (PhD) in Management. Currently, he also serves on the board of directors of various other companies. He is also an international expert and trainer for the United Nations Industrial Development Organization.

Ms. Sujana Shah
Independent Director

Mrs. Sujana Shah, a practicing Chartered Accountant has vast experience of nearly two decades across the domain of finance, accounts, audit, direct and indirect taxes, banking and treasury. Currently, she serves as a partner of V. R. Shah & Associates, Chartered Accountants. She has also audited many reputed public banks in India as Statutory and Internal Auditor.

Thank You

For further information, please contact:

Jigar Todi
Investors Relation & Corporate Strategist

+91 9512049871
ircs3.corp@shalby.org